drugset
drugset / Trial / NCT00280995

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

NCT00280995 ↗

Phase 2 Completed 12 enrolled Kastle Therapeutics, LLC Ionis Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 as add-on therapy in subjects with Homozygous Familial Hypercholesterolemia

Timeline

Start
2006-01
Primary completion
2007-04
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject mipomersen Antisense oligonucleotide 50 mg Subcutaneous
Subject mipomersen Antisense oligonucleotide 100 mg Subcutaneous
Subject mipomersen Antisense oligonucleotide 200 mg Subcutaneous
Subject mipomersen Antisense oligonucleotide 300 mg Subcutaneous

Indications

familial hypercholesterolemia